Immuneering Corp (IMRX) stock
IMRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.71+0.04 (+1.09%)
Close on Nov 13, 2026Market cap $240.27MP/E –Yield –
Immuneering profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Immuneering's profit margin for the twelve months ending Sep 30, 2023 was -11348064.0%. For fiscal 2022 it was -15937.3%, against -1612.3% the year before.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | -15937.3% | −14325.0 |
| FY2021 | Dec 31, 2021 | -1612.3% | −875.2 |
| FY2020 | Dec 31, 2020 | -737.2% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q4 FY2022 | Dec 31, 2022 | -2911112.3% | −2905424.1 |
| Q3 FY2022 | Sep 30, 2022 | -33466.2% | −31696.1 |
| Q2 FY2022 | Jun 30, 2022 | -12208.7% | −10998.5 |
| Q1 FY2022 | Mar 31, 2022 | -7020.4% | −6187.8 |
| Q4 FY2021 | Dec 31, 2021 | -5688.2% | −4810.7 |
| Q3 FY2021 | Sep 30, 2021 | -1770.1% | −1125.6 |
| Q2 FY2021 | Jun 30, 2021 | -1210.2% | −460.6 |
| Q1 FY2021 | Mar 31, 2021 | -832.6% | – |
| Q4 FY2020 | Dec 31, 2020 | -877.5% | – |
| Q3 FY2020 | Sep 30, 2020 | -644.5% | – |
| Q2 FY2020 | Jun 30, 2020 | -749.6% | – |
See a number that looks wrong?